Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More
X
publication

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias


Thijssen, R. et al.
Blood (2021)
Abstract

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced clinically relevant responses in blood cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1 were applied. Strikingly, tumor cells with TP-53 dysfunction escaped and thrived over time if inhibition of BCL-2 or MCL-1 was sublethal, in part because of an increased threshold for BAX/BAK activation in these cells. Our study revealed the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconciled the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia. In contrast to BH3-mimetics targeting just BCL-2 or MCL-1 at doses that are individually sublethal, a combined BH3-mimetic approach targeting both prosurvival proteins enhanced lethality and durably suppressed the leukemia burden, regardless of TP53 mutation status. Our findings highlight the importance of using sufficiently lethal treatment strategies to maximize outcomes of patients with TP53-mutant disease. In addition, our findings caution against use of sublethal BH3-mimetic drug regimens that may enhance the risk of disease progression driven by emergent TP53-mutant clones.



Authors

Thijssen, R., Diepstraten, S.T., Moujalled, D., Chew, E., Flensburg, C., Shi, M.X., Dengler, M.A., Litalien, V., MacRaild, S., Chen, M., Anstee, N.S., Reljić, B., Gabriel, S.S., Djajawi, T.M., Riffkin, C.D., Aubrey, B.J., Chang, C., Tai, L., Xu, Z., Morley, T., Pomilio, G., Bruedigam, C., Kallies, A., Stroud, D.A., Bajel, A., Kluck, R.M., Lane, S.W., Schoumacher, M., Banquet, S., Majewski, I.J., Strasser, A., Roberts, A.W., Huang, D.C.S., Brown, F.C., Kelly, G.L., Wei, A.H.



VIEW

publication
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O.
Cancer Cell (2021)
publication
Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis
Dillon, L.W.
Blood Cancer Discovery (2021)
publication
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Ren, A.A.
Nature (2021)
publication
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Wang, F.
Nature Communications (2021)
REQUEST QUOTE